||Beta-1 adrenergic receptor ||C07AB09 ||For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention. |
||Calcitonin receptor ||R01AC05 ||Used in patients with allergic conjunctivitis. |
||C-X-C chemokine receptor type 4 ||L01XE24 ||Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. |
||Inositol phosphorylceramide synthase ||L04AC02 ||For prophylactic treatment of kidney transplant rejection |
||Retinoic acid receptor gamma;Retinoic acid receptor beta;Retinoic acid receptor RXR-gamma;Retinoic acid receptor RXR-beta;Retinoic acid receptor alpha;Retinoic acid receptor RXR-alpha;Prostaglandin G/H synthase 2 ||D10AD03 ||For the topical treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back. |
||Calcitonin receptor ||J01MA09 ||For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae). |
||Cyclin-dependent kinase 2 ||J01ED01 ||For use in the treatment of infections. |
||Dihydroorotate dehydrogenase (quinone), mitochondrial ||N02CC02 ||For the acute treatment of migraine attacks with or without aura in adults. |
||Epidermal growth factor receptor;Receptor tyrosine-protein kinase erbB-2;Receptor tyrosine-protein kinase erbB-4 ||L01XE13 ||Afatinib is a kinase inhibitor indicated as monotherapy  for the first-line [Label] treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test [Label], and (b) adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy [Label].
Recently, as of January 2018, the US FDA approved a supplemental New Drug Application for Boehringer Ingelheim's Gilotrif (afatinib) for the first line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . The new label includes data on three additional EGFR mutations: L861Q, G719X and S768I . |
||Ornithine aminotransferase, mitochondrial;Ornithine carbamoyltransferase, mitochondrial;Arginase-1;Ornithine decarboxylase antizyme 1;Low affinity cationic amino acid transporter 2;Mitochondrial ornithine transporter 2;Cationic amino acid transporter 4;Hi ||A05BA06 ||Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing. |
||Potassium-transporting ATPase alpha chain 1 ||A02BD06 ||For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. |
||Synaptic vesicular amine transporter;Sodium-dependent noradrenaline transporter;Sodium-dependent dopamine transporter;Trace amine-associated receptor 1;Alpha-1A adrenergic receptor;Alpha-1B adrenergic receptor ||N06BA02 ||Used to treat attention deficit hyperactivity disorder (ADHD). |
||Chymotrypsin-like elastase family member 1 ||N05CC05 ||Paraldehyde was used historically as a sedative and hypnotic . It has been used in the treatment of seizures as an anticonvulsant . |
||C-X-C chemokine receptor type 4 ||L01XD01 ||Indicated in the treatment of esophageal cancer. |
||Cyclin-dependent kinase 2 ||G01AE10 ||Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well.
Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected. |
||DNA;Nuclear receptor subfamily 1 group I member 2 ||L01AA01 ||Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. |
||Muscarinic acetylcholine receptor M1;Muscarinic acetylcholine receptor M2;Muscarinic acetylcholine receptor M3 ||R03BB01 ||For maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. |
||Potassium-transporting ATPase alpha chain 1 ||A02BD04 ||Pantoprazole Injection:
Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis
Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time [Label].
Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome
Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions [Label].
Pantoprazole Extended-Release Tablets/Oral suspension:
Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined .
Maintenance of healing of erosive esophagitis
Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD .
Pathological hypersecretory conditions including Zollinger-Ellison syndrome
Indicated for the long-term treatment of the above conditions . |
||Sodium/potassium-transporting ATPase subunit alpha-1 ||D01AE14 ||Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum. |
||Vanilloid receptor ||A10BA01 ||For the reatment of type II diabetes mellitus. |